- 12,313 shares issued, raising DKK 17.1 million.
- Shares listed on Nasdaq Copenhagen post-registration.
- Total share capital now 64,250,721 shares.
- Capital increase expected to finalize shortly.
Capital Increase Details
Genmab A/S announced a share capital increase of 12,313 shares due to employee warrant exercises. The shares are issued without preemption rights for existing shareholders and are subscribed in cash at varying prices per share, ranging from DKK 1,147.50 to DKK 1,615.00. This capital increase results in proceeds of approximately DKK 17.1 million for the company.
Share Characteristics
The new shares are ordinary, freely transferable, and carry no special rights. They entitle holders to dividends and other company-related rights from the time of subscription. These shares will be listed on Nasdaq Copenhagen following registration with the Danish Business Authority.
Impact on Share Capital
Post-increase, Genmab's total nominal share capital stands at DKK 64,250,721, comprising 64,250,721 shares, each with a nominal value of DKK 1. This adjustment corresponds to approximately 0.02% of the company's share capital.
Regulatory Compliance
The capital increase aligns with section 32 of the Danish Capital Markets Act No. 1493 of November 18, 2025. The process is expected to be finalized shortly, ensuring compliance with relevant regulations.
